Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Celgene Corporation.

Advances In™ Hematology: Translating Recent Evidence into the Treatment of Myelodysplastic Syndromes

Release Date: August 30, 2019
Expiration Date: August 30, 2020
Media: Internet - based

Activity Overview

The correct diagnosis and classification of myelodysplastic syndrome (MDS) subtype is an important component to determining best therapeutic options for each patient. Risk stratification systems allow clinicians to categorize patient risk level and further determine best therapeutic options for patients with MDS. As data continue to be collected and reported from many trials, it is paramount that healthcare providers are kept up-to-date on forthcoming treatment options and recruiting trials that may be the best therapeutic option for patients. Recent reports from clinical trial data offer potential for changes to treatment paradigms for patients with MDS that need to be incorporated into the treatment decision-making process, as well as the into strategies for management of anemia and low platelet count.

To help you meet this challenge, Advances In™ Hematology: Translating Recent Evidence Into the Treatment of Myelodysplastic Syndromes will feature a series of video interviews with top knowledge experts in MDS addressing the accurate diagnosis of MDS, best practices in risk stratification of patients with MDS, and explaining how clinical challenges that are commonly observed can be overcome, as well as reviewing novel therapeutic options for patients with low- and high-risk MDS.

Benefits of Participating

  • Increase knowledge and competence regarding diagnostic and prognostic assessment of MDS.
  • Learn strategies to effectively manage cases with anemia and low platelet count within the context of best practice management of patients with MDS.
  • Build confidence in knowledge of how to optimally treat with targeted therapies and integrate novel therapeutics into clinical practice.
  • Improve knowledge in the best practice management of patients after treatment failure.
  • Increase understanding of novel mechanisms of action of agents in development for the treatment of MDS and the implications for future practice.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Celgene Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps

Target Audience

This educational activity is directed toward medical oncologists and hematologists who treat patients with myelodysplastic syndromes. Nurse practitioners, physician assistants, pharmacists, and other health care professionals interested in the treatment of MDS will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Describe the current categorization of MDS disease and how risk stratification impacts clinical decision-making
  • Summarize evidence-based diagnostic and therapeutic strategies for the treatment of MDS
  • Assess how individual patient characteristics can impact outcomes in MDS, including response to therapies, survival, or progression to AML
  • Define the role of new and emerging therapies and their clinical applications to the future of MDS management

Faculty, Staff, and Planners’ Disclosures


David Steensma
David Steensma, MD
Associate Professor of Medicine
Harvard Medical School
Clinic Director, Center for Prevention of Progression
Institute Physician, Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Consultant: Astex, Stemline, Forty Seven, Pfizer, Summer Road; Shareholder: Array, Arrowhead.

Mikkael Sekeres
Mikkael Sekeres, MD, MS
Professor of Medicine
Director, Leukemia Program
Vice-Chair, Clinical Research
Cleveland Clinic
Cleveland, OH

Disclosures: Consultant: Celgene Corporation, Takeda/Millennium.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or the company that provided commercial support for this program.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By